0.260
0.02 (8.38%)
| Previous Close | 0.240 |
| Open | 0.244 |
| Volume | 255,705 |
| Avg. Volume (3M) | 125,993 |
| Market Cap | 1,593,575 |
| Price / Sales | 1.36 |
| Price / Book | 13.74 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -2,044.08% |
| Diluted EPS (TTM) | -4.33 |
| Quarterly Revenue Growth (YOY) | 13.40% |
| Total Debt/Equity (MRQ) | 1.13% |
| Current Ratio (MRQ) | 1.58 |
| Operating Cash Flow (TTM) | -11.04 M |
| Levered Free Cash Flow (TTM) | -5.86 M |
| Return on Assets (TTM) | -154.25% |
| Return on Equity (TTM) | -688.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Helius Medical Technologies, In | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 0.32% |
| % Held by Institutions | 4.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Grant Private Wealth Management Inc | 31 Dec 2024 | 37,193 |
| Fedenia Advisers Llc | 31 Dec 2024 | 100 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Apr 2025 | Announcement | Helius Medical Technologies Announces Reverse Stock Split |
| 13 Mar 2025 | Announcement | Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary |
| 11 Mar 2025 | Announcement | Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |